ORIONS Money Stocks

[BioSpecialist]

AXSM (MC $85 M)(Cash $50 M) 5x BIG Phase 3 in various indications targeting large Markets with first interim results in 2H 2017 = 2000% POTENTIAL..UNKNOWN LOW FLOAT GEM !!!

Undiscovered and massive undervalued Biotech Stock with lots of Big News on the way.This Stock is brutally undervalued with a Market cap of just $85 million and $50 million in cash .Founder and Ceo is the larget shareholder holding over 7 million shares (30%) more than 50% of O/S is owned by Insider and Institutions which is a great sign .

This undiscovered stock could be the next 10 bagger gem if just one of their 5 ongoing Phase 3 programs is successful .GL

Axsome (AXSM)

Market-Cap: $85 Million
Cash: $50.6 Million(cash runway into the first quarter of 2019.)
Price:$3.70

Shares Out: 23 Million

Anticipated Near-Term Clinical Milestones

Clinical Trial Initiations: -- Phase 2/3 clinical trial of AXS-05 in AD agitation (2Q 2017)

Clinical Trial Readouts:

-- Phase 3 COAST-1 trial of AXS-02 in knee OA associated with BMLs, interim analysis (3Q 2017)

-- Phase 3 CREATE-1 trial of AXS-02 in CRPS, interim efficacy analysis (4Q 2017)

-- Phase 3 STRIDE-1 trial of AXS-05 in TRD, top-line data (1Q 2018)

New Presentation April
http://phx.corporate-ir.net/External.File?item=UGFyZW50SUQ9NjY0Mzk1fENoaWxkSUQ9MzcyMTk4fFR5cGU9MQ==&t=1

HUGE Pipeline targeting Billion Dollar Markets:
http://axsome.com/wp-content/uploads/2016/11/Axsome_Dec2016_Pipeline.png

AXS-05 Treatment Resistant Depression in Phase 3 -(Only 1 approved drug for TRD = unmet medical need. 3M patients in the U.S.)

AXS-05 Agitation in Alzheimer’s Disease in Phase 2/3 -(No approved medication = unmet medical need. 2M patients in the U.S.)

AXS-02 Complex Regional Pain Syndrome (CRPS) in Phase 3 (Orphan+Fast Track Status) -(No approved drug = high unmet need. 80,000 new cases per year in the U.S.)

AXS-02 Knee Osteoarthritis (OA) with Bone Marrow Lesions (BMLs) in Phase 3 (SPA & Fast Track) -(7M patients in the U.S.)

AXS-02 Chronic Low Back Pain(CLBP) with Modic Changes (MCs) in Phase 3 -(1.6M patients in the U.S.)

Major Shareholders

Herriott Tabuteau, MD 7 351 729 38,4%
Fidelity Management & Research Co. 2 361 625 12,3%
JPMorgan Asset Management (UK) Ltd. 1 432 456 7,48%
Mark Coleman, MD 647 998 3,38%
BlackRock Fund Advisors 426 837 2,23%
Stifel Trust Co., NA 415 279 2,17%
The Vanguard Group, Inc. 272 189 1,42%
Lombard Odier Asset Management (USA) Corp. 250 000 1,31%
JPMorgan Investment Management, Inc. 156 625 0,82%
SSgA Funds Management, Inc. 134 688 0,70%